⚕Disclaimer: This content is for educational and informational purposes only. It is not intended as medical advice or a substitute for professional medical consultation. Always consult a qualified healthcare provider before starting any new treatment.

TB-500

Also known as: Thymosin Beta-4 Fragment

Healing & Recovery

Molecular Weight

~4963 Da

A synthetic peptide fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair, studied primarily in preclinical research.

TB-500 is a synthetic peptide derived from thymosin beta-4, a naturally occurring 43-amino-acid protein found throughout the human body. Thymosin beta-4 plays fundamental roles in cell migration, blood vessel formation, and tissue repair. TB-500 represents a specific active fragment of this protein and has been studied primarily in preclinical research for its potential regenerative properties. While TB-500 is not FDA-approved for any medical condition, it has become one of the more commonly discussed peptides in regenerative medicine and recovery-focused clinical settings.

What Is TB-500?

TB-500 is a synthetic version of a 17-amino-acid active region within thymosin beta-4. The full thymosin beta-4 protein is expressed in virtually all human cell types and is particularly concentrated in blood platelets, wound fluid, and tissues undergoing repair or regeneration. Thymosin beta-4 is one of the most abundant members of the beta-thymosin family, a group of small proteins originally identified in the thymus gland. TB-500 has a molecular weight of approximately 4963 Da. Its structure is centered around the actin-binding domain of thymosin beta-4, which researchers believe is responsible for much of the protein full biological activity related to cell movement and tissue repair.

How TB-500 Is Studied

Research on TB-500 and its parent protein thymosin beta-4 has been conducted primarily in animal models and cell culture systems. Published studies have investigated potential effects on dermal wound healing, cardiac tissue repair following ischemic injury, corneal wound healing, and musculoskeletal injury recovery. Equine research has been particularly notable, with studies examining thymosin beta-4 in racehorses for tendon and ligament recovery. In cell culture, thymosin beta-4 has been shown to promote endothelial cell migration and tube formation, processes essential for blood vessel development. While these preclinical findings have generated significant interest, human clinical trials specifically evaluating TB-500 as a therapeutic agent remain limited in number and scope.

Proposed Mechanisms of Action

The primary proposed mechanism of TB-500 involves its interaction with actin, a structural protein that forms the cytoskeleton of cells. By sequestering G-actin monomers, thymosin beta-4 regulates actin polymerization, which directly affects cell shape, movement, and migration. This cell migration-promoting effect is considered central to the wound healing properties observed in research. Additionally, researchers have studied TB-500 for potential anti-inflammatory effects, noting modulation of inflammatory markers in some animal models. Angiogenesis promotion, or the formation of new blood vessels, is another proposed mechanism. These new blood vessels could theoretically improve blood supply to injured tissues, supporting the healing process. Some studies have also examined potential effects on collagen deposition and extracellular matrix remodeling.

Common Goals Associated with TB-500

TB-500 is most commonly discussed in relation to recovery from musculoskeletal injuries. Patients researching peptide options for tendon injuries, muscle strains, and joint recovery frequently encounter TB-500 in clinical literature and provider discussions. Some practitioners also discuss it in the context of muscle growth and body composition goals, as the tissue repair processes supported by thymosin beta-4 may contribute to muscle recovery after intense training. The peptide also appears in longevity and wellness discussions, though evidence for broad systemic benefits remains preliminary.

How Clinics May Offer TB-500 Therapy

Clinics offering TB-500 typically administer it via subcutaneous injection, which is the most common route used in clinical settings. Some providers prescribe an initial loading phase at a higher frequency, followed by a maintenance phase at reduced frequency. Treatment durations commonly range from four to eight weeks depending on the clinical goal and provider protocol. As with other compounded peptides, TB-500 should be sourced from FDA-registered compounding pharmacies that adhere to current good manufacturing practice guidelines. Clinics that include TB-500 in their formulary should conduct a thorough medical evaluation before prescribing.

Safety and Regulatory Status

TB-500 is not FDA-approved for any human medical indication. When used in clinical practice, it is prescribed off-label by licensed physicians and prepared by compounding pharmacies. The human safety data for TB-500 is limited, with most safety observations coming from animal research and small clinical series. Thymosin beta-4 has a longer research history than TB-500 specifically, and some safety data exists from clinical investigations of the full protein in wound healing contexts. However, the safety profiles of the full protein and the synthetic fragment may differ. Potential risks and drug interactions are not well characterized. The FDA regulatory landscape for compounded peptides continues to evolve, and patients should stay informed about any changes that may affect availability.

Comparison with Related Peptides

TB-500 is most frequently compared to BPC-157, as both are studied in the context of tissue repair and recovery. The key difference lies in their proposed mechanisms. TB-500 is primarily associated with actin regulation and cell migration, while BPC-157 research has focused on growth factor modulation and nitric oxide pathways. Some clinical protocols combine both peptides based on the rationale that their complementary mechanisms may provide synergistic recovery support, though controlled clinical evidence for this approach is lacking. Compared to growth hormone secretagogues like ipamorelin and CJC-1295, TB-500 operates through entirely different biological pathways and targets tissue repair rather than hormonal optimization. Unlike semaglutide, TB-500 has no FDA-approved indications and a substantially different mechanism of action.

Related Goals

Recovery

Peptides investigated in preclinical research for their potential roles in tissue repair, wound healing, and recovery from musculoskeletal injuries.

Muscle Growth

Peptides researched for potential effects on lean body mass, growth hormone stimulation, and body composition improvements.

Compare Related Peptides

BPC-157

A synthetic pentadecapeptide derived from a protective protein found in human gastric juice, investigated in preclinical research for tissue repair and gastrointestinal protection.

CJC-1295

A synthetic analog of growth hormone-releasing hormone (GHRH) designed for sustained growth hormone elevation through extended half-life.

Ipamorelin

A selective growth hormone secretagogue peptide studied for its ability to stimulate growth hormone release with fewer side effects compared to earlier secretagogues.

Semaglutide

An FDA-approved GLP-1 receptor agonist prescribed for type 2 diabetes management and chronic weight management in eligible patients.

Find Peptide Clinics Near You

Peptide Clinics in Austin — Directory & Guide

Find peptide therapy clinics in Austin, TX. Compare providers, learn about treatments, and understand what to look for in an Austin peptide clinic.

Peptide Clinics in Los Angeles — Directory & Guide

Find peptide therapy clinics in Los Angeles. Compare providers, learn about treatments, and understand what to look for in an LA peptide clinic.

Peptide Clinics in Miami — Directory & Guide

Find peptide therapy clinics in Miami, FL. Compare providers, learn about available treatments, and understand what to look for in a Miami peptide clinic.

Peptide Clinics in New York — Directory & Guide

Find peptide therapy clinics in New York City. Compare providers, learn about treatments, and understand what to look for in a NYC peptide clinic.

Peptide Clinics in Scottsdale — Directory & Guide

Find peptide therapy clinics in Scottsdale, AZ. Compare providers, learn about treatments, and understand what to look for in a Scottsdale peptide clinic.

Frequently Asked Questions

What is TB-500?

TB-500 is a synthetic peptide fragment derived from thymosin beta-4, a naturally occurring 43-amino-acid protein found throughout the human body. Thymosin beta-4 is involved in cell migration, blood vessel formation, and tissue repair. TB-500 represents a specific active region of this protein and has been studied primarily in preclinical research for regenerative applications.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a synthetic fragment representing a specific active region of the full thymosin beta-4 protein. While they share related biological activity, TB-500 is not identical to the complete 43-amino-acid thymosin beta-4 protein. The pharmacological properties and clinical effects may differ between the fragment and the full protein.

Is TB-500 FDA-approved?

No. TB-500 is not FDA-approved for any human medical indication. It is a research peptide that, when used clinically, is prescribed off-label by licensed physicians and prepared by compounding pharmacies. Patients should verify that their provider sources TB-500 from an FDA-registered compounding facility.

Can TB-500 be combined with BPC-157?

Some clinical protocols use TB-500 and BPC-157 together based on the rationale that they target different mechanisms of tissue repair. TB-500 is associated with cell migration via actin regulation, while BPC-157 is studied for growth factor modulation. However, evidence for the combination approach comes primarily from clinical observation, not controlled clinical trials.

How is TB-500 administered?

TB-500 is typically administered via subcutaneous injection. Common protocols involve an initial loading phase at higher frequency, followed by a maintenance phase at reduced frequency. Treatment durations commonly range from four to eight weeks. As with all peptide therapies, TB-500 should only be used under the guidance of a qualified healthcare provider.

Last reviewed: 3/14/2026